Data as of Dec 26
| +1.51 / +0.44%|
The 22 analysts offering 12-month price forecasts for Biogen have a median target of 382.50, with a high estimate of 474.00 and a low estimate of 285.00. The median estimate represents a +11.71% increase from the last price of 342.40.
The current consensus among 25 polled investment analysts is to Buy stock in Biogen. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.